Rznomics joins Lilly Gateway Labs to advance RNA therapy research
Biopharmaceutical firm Rznomics joined Lilly Gateway Labs in San Diego on 24 August 2026 to accelerate clinical development of its ribonucleic acid based gene therapies
SEONGNAM, South Korea - Biopharmaceutical firm Rznomics Inc. has announced its partnership with Lilly Gateway Labs in San Diego, California. The collaboration aims to advance RNA-based gene therapies and strengthen Rznomics' position in the biotech industry. Lilly Gateway Labs, part of Lilly Catalyze360, offers wet lab facilities and connections to Lilly scientists and executives.
This move enables Rznomics to accelerate candidate discovery and development across its extensive gene database, which includes over 200 disease targets. CEO Seong-Wook Lee emphasized the significance of this milestone, stating that the partnership will help drive long-term efforts to establish global clinical infrastructure and expand strategic partnerships for Rznomics' lead pipelines.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
